Non-invasive diagnostic system for determining oocyte quality and reproductive aging

Background

Female fertility is fundamentally linked to reproductive aging, characterized by a progressive decline in oocyte viability. As women enter their thirties, oocyte quality diminishes, accelerating significantly during their forties. High oocyte quality is essential for successful fertilization and healthy pregnancies. Conversely, age-related decline in egg viability drives adverse outcomes, including elevated infertility rates, miscarriages, and chromosomal abnormalities like Down syndrome. Consequently, there is a critical need in reproductive medicine for reliable diagnostic tools capable of accurately evaluating oocyte health to guide family planning.

Despite this need, current clinical methodologies are fundamentally inadequate for evaluating true oocyte quality. Standard diagnostic practices primarily measure oocyte quantity, relying heavily on indirect metrics such as antral follicle counts and hormone level assessments like FSH and AMH. While these tests estimate the remaining ovarian reserve, they fail to provide actionable insights into the actual fertilization potential of the eggs. Furthermore, procedures attempting to directly evaluate oocyte quality are highly invasive. These techniques often necessitate the physical extraction and subsequent destruction of the oocyte itself, rendering the evaluated egg completely unusable for future reproductive efforts.

Technology

This diagnostic technology evaluates oocyte quality and reproductive aging by analyzing gene expression profiles from non-invasive cell samples, such as blood, saliva, or urine. Instead of examining the oocytes directly, the system measures the expression levels of specific age-correlated biomarkers—including genes linked to DNA repair, mitochondrial function, and insulin/IGF-1 signaling—using assays like RT-PCR or ELISA. It then applies statistical algorithms and FisherZ scores to compare the patient’s molecular profile against a standardized genomic reference library. This calculation generates a personalized reproductive age score, providing a quantitative assessment of oocyte viability relative to the patient’s chronological age.

What differentiates this solution is its ability to accurately measure egg quality rather than just quantity without harming the oocyte. Traditional clinical methods, such as follicle counts or hormone level testing, primarily estimate oocyte reserves and often require invasive procedures that can damage the egg. In contrast, this technology leverages systemic biomarkers found in easily accessible peripheral tissues to directly predict fertilization potential and pregnancy viability. By translating complex genomic data into actionable insights, it enables the creation of practical diagnostic kits, empowering women with proactive, personalized fertility tracking and management.

Benefits

• Non-Invasive Testing: Eliminates the need for invasive procedures by utilizing easily accessible cell samples (such as blood, saliva, or urine), completely avoiding potential harm or destruction to the oocytes.
• Direct Assessment of Oocyte Quality: Evaluates the actual viability and quality of the eggs rather than just estimating quantity, overcoming a major limitation of traditional clinical fertility tests.
• Highly Accurate and Quantitative: Delivers a precise “reproductive age” score by leveraging advanced statistical algorithms to compare a patient’s gene expression profile against comprehensive genomic reference libraries.
• Convenient and Accessible: Enables easy testing through diagnostic kits that feature visual indicators, making the solution suitable for both professional clinical environments and convenient at-home use.
• Proactive Health Monitoring: Allows for regular, periodic tracking of reproductive health, empowering women to monitor their biological aging and assess the impact of lifestyle or medical interventions over time.
• Informed Decision-Making: Equips patients and clinicians with personalized, actionable insights to better plan for childbearing, egg freezing, or assisted reproductive technology (ART) treatments.

Applications

• At-home fertility testing kits
• Egg freezing viability assessment
• IVF success probability prediction
• Reproductive aging monitoring
• Family planning timing guidance

Additional info

This diagnostic methodology evaluates oocyte quality and reproductive aging by analyzing gene expression profiles in non-invasive samples like blood or saliva. Utilizing RT-PCR or ELISA, it measures biomarkers within pathways such as insulin/IGF-1, DNA repair, and mitochondrial function. Statistical algorithms apply FisherZ scores to compare profiles against age-correlated reference libraries, generating a reproductive age score that quantifies cellular viability relative to chronological age, enabling precise fertility assessment.